CYMABAY THERAPEUTICS INC's ticker is CBAY and the CUSIP is 23257D103. A total of 113 filers reported holding CYMABAY THERAPEUTICS INC in Q2 2021. The put-call ratio across all filers is 1.67 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $350,310 | +430.8% | 23,495 | +24.1% | 0.00% | – |
| Q3 2022 | $66,000 | +106.2% | 18,932 | +76.7% | 0.00% | – |
| Q2 2022 | $32,000 | -17.9% | 10,714 | -13.5% | 0.00% | – |
| Q1 2022 | $39,000 | -22.0% | 12,391 | +7.4% | 0.00% | – |
| Q2 2021 | $50,000 | +614.3% | 11,540 | +602.4% | 0.00% | – |
| Q1 2021 | $7,000 | -93.4% | 1,643 | -91.1% | 0.00% | – |
| Q4 2020 | $106,000 | -45.1% | 18,450 | -31.0% | 0.00% | -100.0% |
| Q3 2020 | $193,000 | +2044.4% | 26,720 | +2211.4% | 0.00% | – |
| Q4 2018 | $9,000 | -80.0% | 1,156 | -66.7% | 0.00% | – |
| Q1 2018 | $45,000 | +87.5% | 3,475 | -15.4% | 0.00% | – |
| Q2 2017 | $24,000 | – | 4,108 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management IV, LLC | 2,254,502 | $20,741,000 | 14.54% |
| Versant Venture Management, LLC | 1,048,601 | $9,647,127,000 | 10.15% |
| Abingworth LLP | 1,147,077 | $10,553,000 | 7.65% |
| Omega Fund Management, LLC | 551,477 | $5,074,000 | 3.67% |
| Opaleye Management Inc. | 665,000 | $6,118,000 | 1.96% |
| DAFNA Capital Management LLC | 361,164 | $3,323,000 | 1.79% |
| Boxer Capital, LLC | 1,012,986 | $9,319,000 | 1.70% |
| Foresite Capital Management III, LLC | 600,000 | $5,520,000 | 1.55% |
| NEXTHERA CAPITAL LP | 536,568 | $4,936,000 | 0.91% |
| Perceptive Advisors | 2,685,882 | $24,710,000 | 0.82% |